Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics - Wikidata - awgldk - TriplyDB

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics

http://www.wikidata.org/entity/Q33400211

about

Advances and challenges in the management of complement-mediated thrombotic microangiopathies Hemolytic uremic syndrome Management of hemolytic-uremic syndrome in children Thrombotic microangiopathy and associated renal disorders.Complement disorders and hemolytic uremic syndrome.Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.Extra-renal manifestations of complement-mediated thrombotic microangiopathies.Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation.First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Fever, Jaundice, Abdominal Pain, Skin Lesions, and Dark Urine for 2 Days.The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study.Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study Anti-complement-factor H-associated glomerulopathies.Occurrence of atypical HUS associated with influenza B.Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report.Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients Fecal diagnostics in combination with serology: best test to establish STEC-HUS.Hepatitis B vaccine-associated atypical hemolytic uremic syndrome.Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.The renal biopsy in the genomic era.Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab.Atypical hemolytic-uremic syndrome due to complement factor I mutation.

P2860

Q26796453-2E2F2E96-3539-4B45-85BC-8A8026450E7A Q26799054-B31284EC-A85F-45BE-999B-838DC6A30F65 Q27002576-02A4C6BE-2280-4283-8686-3D72E59ACB90 Q33402372-DD2FD126-A736-482D-A88E-9E01AA75FA59 Q33405802-7CFBFA43-E188-4C11-B93B-BDDFE0C3B25D Q33406025-61F1472E-DF55-4CD4-A204-262B10FEBE88 Q33406584-AC8CCCC8-C154-43A3-B108-63E25EC60ED1 Q33408733-2C9D8654-B5A2-46A4-9C21-F31CDCC0E510 Q33409198-78ACB3E6-07B2-4F3C-95AC-96B3DF230EA4 Q33415767-742DC26C-DD2B-41FA-A5E7-EC4979F3BEE8 Q33417375-9206B99B-79F9-46F7-9A2F-0FD02935EDAC Q33417644-D2065923-C92D-4918-88B1-B636F13EC7B4 Q33417814-340DEC92-BF41-439E-A053-34A63E76ED7F Q33418632-E2D5D0B7-C6B8-4365-A706-8EEAFC09B89F Q33418916-28BB6C0F-1C45-4493-9E38-2ED14FB569A0 Q33419275-985B9502-AA11-4DC0-8757-ADDF3135F406 Q33419905-031F16A7-7D95-476C-8066-A02C9CBCCB13 Q33421861-FC78AAA5-7944-4E7F-95AC-0CD12E82787D Q33423489-288025A4-91CF-47BD-B748-D56422EF35F9 Q33427495-FD4EBC68-34F3-448F-B7D3-30B69F3398D8 Q33428892-4728A1C9-D67B-4DB0-8242-AC8D0AC66FA3 Q33432006-8FD1328A-C1CD-488C-933A-B420B88F1D0F Q33434103-CC98D4F9-14FA-4FCB-8206-661B5650C759 Q33438621-41B0A883-27F9-411E-B997-492BF2B82D4A Q33560817-3557890F-3F32-44AB-A356-93E981DC90E7 Q33705135-7564FE13-BC4A-4719-AEF4-1837DEF41EA3 Q33818095-10ADF864-91B1-464E-9339-4FCD48B042DE Q35750545-E6CBD449-667C-47DD-9CBF-FD130AE33E40 Q36241014-DEF0BB5B-CC13-4E45-B81A-8F61D28203F7 Q37290075-AAD1E789-3975-4483-8D32-EB267A34C0FD Q37418974-C896A926-A9BD-4470-A085-C9C785A9579B Q37547496-C524DF66-6C15-4518-BA92-FA69241109E4 Q38062343-F341CF40-8061-45C1-A3B2-8254646D8941 Q38118112-79CB219B-5736-46C0-B913-AA206F025400 Q38862309-9AAE7D0B-867B-4270-8E40-29859AD85844 Q39112532-81953903-211E-407A-89E7-351B1F526BF8 Q40278428-99018582-EA45-4F2E-AF0D-9DCDBEF99F7D Q42650328-78998E74-4592-4898-862B-7C2C231B9446 Q43213346-52A3F65A-831A-4D09-83EF-F03242C52D9C Q47094087-94705A8D-0762-4A00-B833-7A578ABE258A

P2860

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics

http://www.wikidata.org/entity/Q33400211

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Atypical hemolytic uremic synd ...... s and clinical characteristics

@ast

Atypical hemolytic uremic synd ...... s and clinical characteristics

@en

type

label

Atypical hemolytic uremic synd ...... s and clinical characteristics

@ast

Atypical hemolytic uremic synd ...... s and clinical characteristics

@en

prefLabel

Atypical hemolytic uremic synd ...... s and clinical characteristics

@ast

Atypical hemolytic uremic synd ...... s and clinical characteristics

@en

P1433

Q33400211-3B691B60-70F1-4192-9D7C-5ADE36AC64F7

P1476

Q33400211-11247421-A959-4DA9-BC81-6980C5168BCE

P2093

Q33400211-398CC030-63DA-4CD3-B061-933DB479A3F3

Q33400211-59D01336-F4B7-4BD8-8674-67ABF9504442

Q33400211-6F482232-E707-4A0D-B8DF-5C71AE7BC3EB

Q33400211-949BB6DC-69B1-487B-A737-AC00143CA71D

Q33400211-9C11E57D-54A6-4982-B6FF-63C905BCBFD2

Q33400211-BDED77A9-4AD9-46C2-8106-56081BD70A00

Q33400211-CA2CB35A-9ECF-4EE5-AF4F-0473B7060B4D

Q33400211-CA51CB3E-DDB7-4B9F-88F4-C8D0DC8456EB

Q33400211-E7055C7A-1EF6-4A46-95CD-912A9E027AB7

Q33400211-F0B4D431-C585-46CA-8832-0A93B015B588

P2860

Q33400211-0898939B-495E-44CA-806A-35E26FEFCE5E

Q33400211-120015E3-3D53-4B9A-87FF-85E360A28052

Q33400211-13C6A34A-F65E-4B4A-B7B5-D05056EC4B0D

Q33400211-20A2B382-3DCB-41A5-B759-8D00663685C4

Q33400211-2790C16E-78DF-4791-999C-38C3DF5FE9D8

Q33400211-2ED95A72-1A9F-4C74-A162-5FAFB800D847

Q33400211-33F02FCB-F5C6-4CAB-A2C8-FAE96FEA6346

Q33400211-38B72B99-2C98-4FC7-9F9B-DA7599F2E819

Q33400211-40356BF6-84D3-4BA5-922A-E199081453D1

Q33400211-4E3FE850-796A-4B7A-9130-8FD0ECD7B9BA

P2888

Q33400211-D2F6D0CA-2E25-42AB-BBE7-8E51034964D9

P304

Q33400211-DE4A7168-4F51-41E2-A448-D025B6129112

P31

Q33400211-41F0A6C4-20A2-4FE5-850D-9264BC974D6B

P356

Q33400211-20994ED7-14E7-4CBA-8DAF-8C9E805E7241

P433

Q33400211-5056D507-18C6-4393-BCBB-802A738ADD42

P478

Q33400211-73E2AC4F-2EE1-4D46-B40D-DF819E704130

P577

Q33400211-F8F7E1E0-36EF-444D-B675-8CA06F2EAAE1

P5875

Q33400211-438D00A3-BB70-4367-923A-06AB0D7D0AA8

P6179

Q33400211-8323B547-A635-439F-9C31-17B020D115DC

P698

Q33400211-13A54FD8-5F70-40DF-8B40-73E9B45A4C6E

P932

Q33400211-73F7090F-0167-4DED-A345-4034AC0E3D9F

P356

S00467-012-2131-Y

P1433

Pediatric Nephrology

P1476

Atypical hemolytic uremic synd ...... s and clinical characteristics

@en

P2093

Amerins van der Vlugt

http://www.w3.org/2001/XMLSchema#string

Dineke Westra

http://www.w3.org/2001/XMLSchema#string

Eiske M Dorresteijn

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Davin

http://www.w3.org/2001/XMLSchema#string

Joanna A E van Wijk

http://www.w3.org/2001/XMLSchema#string

Koen Van Hoeck

http://www.w3.org/2001/XMLSchema#string

Lambertus P van den Heuvel

http://www.w3.org/2001/XMLSchema#string

Lianne M Geerdink

http://www.w3.org/2001/XMLSchema#string

Marc R Lilien

http://www.w3.org/2001/XMLSchema#string

Martin Kömhoff

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)

Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.

P2888

s00467-012-2131-y

P304

1283-1291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-012-2131-Y

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221696644

http://www.w3.org/2001/XMLSchema#string

P6179

1002445932

http://www.w3.org/2001/XMLSchema#string

P698

22410797

http://www.w3.org/2001/XMLSchema#string

P932

3382652

http://www.w3.org/2001/XMLSchema#string